Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net loss	$ (56,942)	$ (44,971)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	317	330
Stock-based compensation	7,417	3,022
Non-cash research and development expenses		20,000
Non-cash lease expense	548	295
Non-cash loss from equity method investment in joint venture		50
Changes in fair value of derivative liability		3,261
Changes in operating assets and liabilities:
Prepaid expenses and other assets	698	(448)
Accounts payable	(4,131)	(364)
Accrued expenses and other current liabilities	504	(114)
Operating lease liabilities	198	(299)
Derivative liability		3,369
Net cash used in operating activities	(51,391)	(15,869)
Investing activities
Purchase of property and equipment	(275)	(540)
Investment in joint venture		(50)
Net cash used in investing activities	(275)	(590)
Financing activities
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs		151,581
Deferred offering costs		(729)
Proceeds from the exercise of stock options	177
Net cash provided by financing activities	177	150,852
Net (decrease) increase in cash, cash equivalents, and restricted cash	(51,489)	134,393
Cash, cash equivalents and restricted cash at beginning of year	276,316	8,188
Cash, cash equivalents and restricted cash at end of year	224,827	142,581
Supplemental cash flow information:
Cash received for interest	157	10
Supplemental schedule of noncash investing and financing activities:
Deferred offering costs in accounts payable and accrued expenses		1,413
Operating lease right-of-use asset obtained in exchange for operating lease liabilities	(15,319)
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	223,355	142,473
Restricted cash	1,472	108
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 224,827	$ 142,581